Short answer
Idexx Laboratories (IDXX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for quarter ended September 30, 2026.
Idexx Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Full financial results available in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1,214M, up 10% organically, confirming broad-based demand and strong commercial execution
- EPS $4.01, up 18% reported and 22% comparable, with operating margin expanding 100 basis points to 33.1%
- Over 1,900 inVue Dx analyzers placed, expanding the installed base to nearly 11,000 and supporting future recurring consumables revenue
- 2026 revenue guidance raised to $4,741M-$4,767M, $32M higher at midpoint, while operating margin guidance declined to 32.1%-32.3%
- 2026 EPS outlook raised to $14.96-$15.16, a $0.25 midpoint increase, despite acquisition-related impacts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Idexx Laboratories 8-K filings
Get the next IDXX 8-K as it lands
Follow IDXX for push alerts, or ask the research agent what this filing means.